iData Insights

Enterococcus faecium Infections - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 17:16 IST

Enterococcus faecium Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Enterococcus Faecium Infections - Pipeline Review, H2 2015 , provides an overview of the Enterococcus Faecium Infections s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Enterococcus Faecium Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Enterococcus Faecium Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173355/enterococcus-faecium-infections-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173355/enterococcus-faecium-infections-pipeline-review-h2-2015

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Enterococcus faecium Infections Overview 10

Therapeutics Development 11

Pipeline Products for Enterococcus faecium Infections - Overview 11

Pipeline Products for Enterococcus faecium Infections - Comparative Analysis 12

Enterococcus faecium Infections - Therapeutics under Development by Companies 13

Enterococcus faecium Infections - Therapeutics under Investigation by Universities/Institutes 15

Enterococcus faecium Infections - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Enterococcus faecium Infections - Products under Development by Companies 19

Enterococcus faecium Infections - Products under Investigation by Universities/Institutes 21

Enterococcus faecium Infections - Companies Involved in Therapeutics Development 22

Alchemia Limited 22

Alvogen Korea 23

Aphios Corporation 24

BioSource Pharm, Inc. 25

Cellceutix Corporation 26

ContraFect Corporation 27

Helix BioMedix, Inc. 28

Hsiri Therapeutics, LLC 29

LegoChem Biosciences, Inc 30

Lytix Biopharma AS 31

Melinta Therapeutics, Inc 32

MGB Biopharma Limited 33

Microbiotix, Inc. 34

MicuRx Pharmaceuticals, Inc. 35

NovaBay Pharmaceuticals, Inc. 36

Novan, Inc. 37

NovoBiotic Pharmaceuticals, LLC 38

Omnia Molecular Ltd. 39

Oragenics, Inc. 40

Sealife PHARMA GMBH 41

Sentinella Pharmaceuticals, Inc. 42

Sumitomo Dainippon Pharma Co., Ltd. 43

TAXIS Pharmaceuticals, Inc. 44

Wockhardt Limited 45

Enterococcus faecium Infections - Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Target 47

Assessment by Mechanism of Action 49

Assessment by Route of Administration 51

Assessment by Molecule Type 53

Drug Profiles 55

auriclosene - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

brilacidin tetrahydrochloride - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BSPC-728 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

CF-304 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

chrysophaentin - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

closthioamide - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Epimerox - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

HB-1345 - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

HT-01 - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

HT-02 - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

IBN-1 - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

LCB-010371 - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

LCB-010699 - Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

LTX-109 - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Marinus - Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

MBX-1162 - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

MGBBP-3 - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

MRX-I - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

MRX-IV - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

MU-1140 - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

NAI-107 - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

NAI-603 - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

NVN-1000 - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

OM-011818 - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

RX-05 - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

RXP-873 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

SLP-0904 - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

SLP-0905 - Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

SM-295291 - Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

SM-369926 - Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

SP-2078 - Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Teixobactin - Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

WCK-4086 - Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Enterococcus faecium Infections - Recent Pipeline Updates 101

Enterococcus faecium Infections - Dormant Projects 119

Enterococcus faecium Infections - Discontinued Products 121

Enterococcus faecium Infections - Product Development Milestones 122

Featured News & Press Releases 122

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I 122

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 122

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 123

Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 123

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 124

Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 124

Appendix 125

Methodology 125

Coverage 125

Secondary Research 125

Primary Research 125

Expert Panel Validation 125

Contact Us 125

Disclaimer 12"

Read More http://www.idatainsights.com/reports-landing-page.php?id=173355/enterococcus-faecium-infections-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects